CareDx, which sells molecular diagnostic tests to monitor heart transplants, refiled on Tuesday with the SEC to raise up to $50 million in an initial public offering. It originally filed for an $86 million IPO in 2007 under the name XDx but withdrew in 2008.
The Brisbane, CA-based company, which was founded in 1998 and booked $23 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol CDNA. CareDx initially filed confidentially on March 31, 2014. Piper Jaffray, Leerink Partners, Raymond James and Mizuho Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
